Core Points - Rosen Law Firm is reminding investors who purchased PubMatic, Inc. securities between February 27, 2025, and August 11, 2025, of the October 20, 2025, lead plaintiff deadline for a class action lawsuit [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] Company Information - The lawsuit alleges that during the Class Period, PubMatic made false and misleading statements regarding its business operations, particularly related to a significant demand side platform buyer shifting clients to a new platform, leading to reduced ad spend and revenue [4] - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]

To join the LifeMD class action, go to https://rosenlegal.com/submit-form/?case_id=43404 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. , /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of LifeMD, Inc. (NASDAQ: LFMD) between May 7, 2025 and August 5, 2025, both dates inclusive (the "Class Period"), of the important October 27, 2025 lead plaintiff deadline in the securities class ac ...

New York, New York--(Newsfile Corp. - October 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of KBR, Inc. (NYSE: KBR) between May 6, 2025 and June 19, 2025, both dates inclusive (the "Class Period"), of the important November 18, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.SO WHAT: If you purchased KBR securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Tronox Holdings plc due to misleading statements and a significant decline in financial performance, urging affected investors to take action before the November 3, 2025 deadline for lead plaintiff applications in a federal securities class action [4][6][9]. Group 1: Company Performance - Tronox reported a significant reduction in TiO2 sales for Q2 2025, attributing the decline to a softer coatings season and increased competition, leading to a lowered full-year revenue guidance and a 60% reduction in dividends [7][8]. - Following the announcement of poor financial results, Tronox's stock price plummeted from $5.14 to $3.19 per share, marking a decline of approximately 38% in just one day [8]. Group 2: Legal Actions - A federal securities class action has been filed against Tronox, with a deadline of November 3, 2025, for investors to seek the role of lead plaintiff [4][9]. - The firm encourages anyone with information regarding Tronox's conduct, including whistleblowers and former employees, to come forward [10].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Quantum Corporation due to allegations of improper revenue recognition and subsequent financial restatements, which have led to significant stock price declines and investor losses [3][5][6]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Quantum Corporation to contact them for discussing legal options, particularly regarding a federal securities class action with a deadline of November 3, 2025, to seek the role of lead plaintiff [3][10]. - The lawsuit claims that Quantum Corporation made false and misleading statements regarding its financial health, specifically related to revenue recognition for the fiscal year ending March 31, 2025, necessitating a restatement of financial statements [5][6]. Group 2: Financial Impact and Stock Performance - On June 30, 2025, Quantum disclosed it would be unable to file its annual financial report on time, leading to a stock price drop of $1.00, or 10.03%, closing at $8.97 per share [6]. - Following an announcement on August 8, 2025, regarding deficiencies in internal controls, Quantum's stock fell by $0.14, or 1.79%, to close at $7.66 per share [8]. - After the resignation of the CEO on August 18, 2025, Quantum's stock price further declined by $0.61, or 8.2%, closing at $6.83 per share [8]. Group 3: Company Background and Recovery Efforts - Faruqi & Faruqi, LLP has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995, indicating a strong track record in securities litigation [4]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Quantum Corporation's conduct to strengthen the case [10].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against LifeMD, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and financial guidance [4][6]. Group 1: Legal Investigation - Faruqi & Faruqi is encouraging investors who suffered losses exceeding a certain amount in LifeMD to contact them for legal options [1]. - The firm has set an October 27, 2025 deadline for investors to seek the role of lead plaintiff in a federal securities class action against LifeMD [4]. - The investigation is focused on claims that LifeMD and its executives made false or misleading statements regarding the company's competitive position and financial guidance [6]. Group 2: Financial Performance and Impact - On August 5, 2025, LifeMD reported its second-quarter financial results, revising its revenue guidance to a range of $250 to $255 million, down from a previous estimate of $268 to $275 million [7]. - Following the announcement of the revised guidance, LifeMD's stock experienced a significant decline of 44.8% on August 6, 2025 [7]. Group 3: Class Action Details - The lead plaintiff in a class action is defined as the investor with the largest financial interest who can adequately represent the class [8]. - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [8].

Core Viewpoint - KBR, Inc. is facing a securities class action lawsuit for failing to disclose material information during the class period from May 6, 2025, to June 19, 2025, which has led to significant stock price declines following negative news related to a joint venture with HomeSafe Alliance [1][3]. Group 1: Lawsuit Details - Investors have until November 18, 2025, to file lead plaintiff applications in the lawsuit against KBR [1]. - The lawsuit is pending in the United States District Court for the Southern District of Texas, under the case name Norrman v. KBR, Inc., et al., No. 25-cv-04464 [5]. - KBR and its executives are accused of violating federal securities laws by not disclosing critical information during the class period [3]. Group 2: Stock Price Impact - On June 19, 2025, HomeSafe Alliance, a joint venture in which KBR holds a 72% economic interest, announced the termination of a significant contract with the U.S. Department of Defense, leading to a drop in KBR's stock price [4]. - Following the announcement, KBR's shares fell by $3.85, or 7.29%, closing at $48.93 on June 20, 2025 [4]. - The stock experienced further decline, dropping an additional $1.30, or 2.65%, to close at $47.63 on June 23, 2025 [4].

Core Points - Rosen Law Firm is reminding purchasers of KBR, Inc. securities from May 6, 2025, to June 19, 2025, about the November 18, 2025, lead plaintiff deadline in a securities class action lawsuit [1][5] - Investors who purchased KBR securities during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - The lawsuit alleges that KBR made materially false and misleading statements regarding its partnership with HomeSafe and the ability to fulfill the Global Household Goods Contract, leading to investor damages when the truth was revealed [5] Next Steps - Interested parties can join the KBR class action by visiting the provided link or contacting the law firm directly for more information [3][6] - A class has not yet been certified, and investors can choose to remain absent or select their own counsel [7] Rosen Law Firm's Credentials - The firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4] - Rosen Law Firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Altimmune, Inc. following a significant decline in its stock price after disappointing trial results for Pemvidutide, urging affected investors to discuss their legal options [1][3][4]. Group 1: Company Overview - Altimmune, Inc. is a biopharmaceutical company involved in developing treatments, including Pemvidutide for MASH [3]. - The company faced a setback when it failed to achieve statistical significance in its Phase 2b MASH trial, leading to inflated expectations prior to the announcement [3]. Group 2: Stock Performance - Following the announcement of the trial results on June 26, 2025, Altimmune's stock price plummeted from $7.71 to $3.61 per share, marking a decline of 53.2% in one day [4]. Group 3: Legal Actions - A federal securities class action has been filed against Altimmune, with a deadline of October 6, 2025, for investors to seek the role of lead plaintiff [1][5]. - The lead plaintiff is defined as the investor with the largest financial interest who can adequately represent the class [5].

Accessibility StatementSkip Navigation Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Quantum Corporation To Contact Him Directly To Discuss Their Options If you suffered losses in Quantum Corporation between November 15, 2024 and August 18, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330Â (Ext. 1310). [You may also click here for additional information] NEW ...